Best-selling in Non-Fiction Books
Save on Non-Fiction Books
- AU $46.25Trending at AU $49.65
- AU $3.73Trending at AU $7.41
- AU $27.04Trending at AU $31.16
- AU $70.90Trending at AU $78.37
- AU $25.16Trending at AU $27.12
- AU $20.50Trending at AU $24.20
- AU $22.60Trending at AU $23.15
About this product
- DescriptionThis Brief defines competitive intelligence (CI) as a tool for making investment decisions within the pharmaceutical industry. It provides an overview of processes that the regulatory affairs professional must take into account when evaluating data impacting product-based risk evaluations. These apply particularly to evaluations that focus on outputs such as regulatory approval, or the commercial impact of product labeling on the sales forecast over a limited timeframe. The Brief also provides an overview of intellectual property assessment that can impact a product's lifespan on the market due to patent protection itself (or loss of patent protection) or via regulatory exclusivity. Case examples are discussed to illustrate the importance of keeping up with the ever-changing regulations, and how to interpret them in the context of CI. In addition, there is a section on virtual data rooms (VDRs) which currently function as the cornerstone of due diligence investigations. While aimed primarily at regulatory affairs professionals in the United States, this publication provides a useful adjunct for other pharmaceutical executives, especially those new to product-based investments, and regulatory affairs professionals in other regions.
- Author BiographyRaymond A. Huml, MS, DVM, RAC is Executive Director of Global Due Diligence in Quintiles Capital Solutions ( Capital ) for Quintiles Transnational Corp. Dr. Huml has over 20 years of experience in the biopharmaceutical industry. In his current position, Dr. Huml identifies risks associated with Quintiles global (US, EU and Japan) product-based investments, working with specialists on all components of the due diligence process, including research and development, commercial, intellectual property, and conflict of interest. He previously worked in Biostatistics, Medical Writing, and Regulatory Affairs Departments in Quintiles Clinical Development Services group. Dr. Huml has authored and co-authored numerous scientific publications, and is a strong supporter of the Regulatory Affairs Professional's Society (RAPS). He holds an MS in Biology from East Stroudsburg University and his DVM from North Carolina State University's College of Veterinary Medicine, and has earned the RAC (US) Certification.
- Author(s)Raymond A. Huml
- PublisherSpringer-Verlag New York Inc.
- Date of Publication07/06/2012
- SubjectClinical Medicine: Professional
- Series TitleSpringerbriefs in Pharmaceutical Science and Drug Development
- Place of PublicationNew York, NY
- Country of PublicationUnited States
- ImprintSpringer-Verlag New York Inc.
- Content Note1 black & white illustrations, 3 colour illustrations, 6 black & white tables, biography
- Weight165 g
- Width155 mm
- Height235 mm
- Spine5 mm
This item doesn't belong on this page.
Thanks, we'll look into this.